Business Wire

nShift: Belgian Companies Must Act Fast to Meet Minimum Delivery Options Requirements

Share

Belgium’s online retailers have just 16 days to comply with a new legal requirement to provide their customers with greater delivery choice. New legislation demands that from 21 September, webshops and ecommerce retailers in Belgium must provide at least two methods for the delivery of products to consumers. Retailers will be free to choose the delivery method but (at least) one of the options is encouraged to be eco-friendly.

It’s why nShift, the global leader in experience and delivery management (DMXM) is introducing a new and limited time offer designed to help retailers comply with the new law and offer a better customer experience. New customers in Belgium will receive 25% off a subscription to any of nShift’s solutions for six months.

Sean-Sherwin Smith, Product Director, Post Purchase at nShift said, “The new law marks a major shift in how online retailers will operate across Belgium. The new rule emphasizes sustainability and customer convenience. It marks a significant change in the regulatory landscape and means multi-carrier capability must be central to how retailers operate in the future.

"Sustainability is a core part of nShift’s offer. Our 1000+ carrier library features numerous sustainable last-mile solutions. Our Checkout functionality makes it easier to quickly badge and label more sustainable delivery options so shoppers can quickly find what they are looking for.”

Multi-carrier capability

Retailers will be able to respond to these changes more easily and efficiently if they work with a delivery management partner that offers multi-carrier capabilities. Beyond meeting the new legal requirement, working with a variety of carriers means retailers can offer real choice to shoppers, gain the agility to adapt to shifting consumer demand, and grow their business. Multi-carrier deliveries enable retailers to:

  • Offer a range of delivery options - shoppers expect to find the shipping solution they seek
  • Boost delivery capacity - making it easier to respond to increased demand
  • Improve delivery quality and efficiency – by gaining real data about the performance of each carrier
  • Grow beyond borders - shipping internationally requires relationships with carrier companies that serve the relevant territories
  • Build the brand and remarket to customers – by taking control of customer communications

Multi-carrier capability is at the heart of nShift’s DMXM suite of solutions. It provides enterprise-grade delivery management with a library of 1000+ ready-made carrier connections. nShift can connect retailers and consumers to over one million PUDO (pick up / drop off) locations. Retailers can automate the carrier-booking and label-printing process. This helps retailers send out more parcels, work with more carriers, and tightly control the delivery experience.

Sherwin-Smith concluded, “Businesses affected by the new law need to act fast but it’s also important they make the necessary adjustments in a scalable and sensible way. They must work with a partner that offers choice and convenience, particularly when it comes to eco-friendly carriers and emissions tracking capabilities.”

For more information on the offer or to find out how nShift could help your business with its multi-carrier offering, please visit our website, www.nshift.com.

About nShift

nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

Notes to editors

Under Article VI.45/2 of the Code of Economic Law, webshops will be required to offer at least two delivery methods, including one that is eco-friendly.

This offer is not available to existing customers and cannot be combined with any other discount or promotion. The offer is valid from 00:01 05 September 2024 until midnight on 31 December 2024.

Full subscription agreement will outline contractual terms, Customer will be granted optional termination 90 days from “Start Date”. A minimum of 14 days’ notice of termination must be given. This email does not represent contractual obligation. Promotion excludes existing “Track” service customers; customers with an existing signed “Track” subscription agreement. nShift AB standard terms and conditions apply. Promotional offer will run until 30th November 2023. nShift reserves the right to close promotional offer.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906823045/en/

Contacts

James Ellerington:
James.Ellerington@fourteenforty.uk / (+44) 07725 534941

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye